BDX · Becton Dickinson & Co
$188.13
-2.08 (-1.09%)
At close · Aug 27
Market Cap
$51.81B
Shares
272.39M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$21.84B
+8.2%
FY2025
Net Income
$1.68B
-1.6%
FY2025
Gross Margin
47.14%
-0.8pp
FY2020
Operating Margin
11.81%
-0.1pp
FY2025
Diluted EPS
$4.58
-0.7%
FY2025
Operating Cash Flow
$3.43B
-10.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $22.42B | $21.84BG | $20.18B | $19.37BG | $18.87B | $19.13B | $16.07B | $17.29B | $15.98B | $12.09B | $12.48B | $10.28B | $8.45B | $8.05B | $7.71B | $7.58B | $7.12B | $6.99B | $6.9B | $6.28B | |
| — | $11.94B | $11.92B | $11.05B | $11.2B | $10.39B | $10.5B | $9.28B | $9B | $8.71B | $6.13B | $6.49B | $5.59B | $4.15B | $3.88B | $3.76B | $3.63B | $3.43B | $3.31B | $3.36B | $3.03B | |
| — | — | — | — | — | — | — | $7.58B | $8.29B | $7.27B | $5.94B | $5.99B | $4.7B | $4.3B | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | 47.14% | 47.94% | 45.48% | 49.14% | 47.99% | 45.66% | 50.92% | — | — | — | — | — | — | — | |
| — | $1.27B | $1.27B | $1.19B | $1.24B | $1.26B | $1.28B | $1.04B | $1.06B | $1B | $770M | $828M | $632M | $550M | $494M | $472M | $470M | $422.77M | $404.57M | — | — | |
| — | $5.55B | $5.28B | $4.86B | $4.72B | $4.71B | $4.72B | $4.19B | $4.33B | $4.02B | $2.91B | $3.01B | $2.56B | $2.15B | $2.42B | $1.92B | $1.82B | $1.69B | $1.68B | $1.67B | $1.58B | |
| — | $1.56B | $1.59B | $1.47B | $1.47B | $1.43B | $1.4B | $1.38B | $1.5B | $1.26B | $553M | $552M | $346M | $84M | $83M | $71M | $54M | $46.96M | — | — | — | |
| — | $2.45B | $2.46B | $2.29B | $2.29B | $2.23B | $2.23B | $2.12B | $2.25B | $1.98B | $1.09B | $1.11B | $891M | $562M | $546M | $511M | $494M | $491.42M | $464.6M | $471.96M | $441.1M | |
| — | — | $275M | $387M | $239M | $123M | $44M | $84M | — | — | $85M | $526M | $271M | — | — | — | — | — | — | — | — | |
| — | $20.1B | $19.26B | $17.78B | $17.26B | $16.59B | $16.88B | $15.16B | $15.53B | $14.47B | $10.57B | $11.05B | $9.21B | $6.84B | $6.8B | $6.15B | $5.92B | $5.54B | $5.4B | $5.41B | $5.1B | |
| — | $2.31B | $2.58B | $2.4B | $2.11B | $2.28B | $2.25B | $912M | $1.76B | $1.51B | $1.52B | $1.43B | $1.07B | $1.61B | $1.25B | $1.56B | $1.67B | $1.58B | $1.59B | $1.49B | $1.18B | |
| — | — | 11.81% | 11.88% | 10.9% | 12.09% | 11.76% | 5.67% | 10.18% | 9.44% | 12.59% | 11.46% | 10.45% | 19.01% | 15.57% | 20.21% | 21.97% | 22.21% | 22.75% | 21.57% | 18.86% | |
| — | $4.77B | $5.04B | $4.68B | $4.4B | $4.51B | $4.48B | $3.03B | $4.01B | $3.49B | $2.61B | $2.54B | $1.97B | $2.17B | $1.8B | $2.07B | $2.16B | $2.07B | $2.05B | $1.96B | $1.63B | |
| — | $590M | $613M | $528M | $452M | $398M | $469M | $528M | $639M | $706M | $521M | $388M | $371M | $135M | $138M | $135M | $84M | $51.26M | $40.39M | $36.34M | $46.42M | |
| — | $23M | $38M | $163M | $49M | $16M | $9M | $7M | $12M | $65M | $76M | $21M | $15M | $46M | $40M | $50M | $43M | — | — | — | — | |
| — | $46M | -$123M | -$28M | -$46M | -$117M | -$99M | $23M | $43M | $305M | -$101M | $11M | $21M | $5M | $9M | -$1M | -$7M | $497K | -$3.85M | -$1.48M | $944K | |
| — | — | — | — | — | — | — | $13M | $18M | $8M | $3M | $8M | $9M | $13M | $5M | $12M | $3M | $4.85M | $4.54M | $4.64M | — | |
| — | $1.79B | $1.88B | $2.01B | $1.66B | $1.78B | $1.69B | $414M | $1.18B | $1.17B | $976M | $1.07B | $739M | $1.52B | $1.17B | $1.47B | $1.62B | $1.57B | $1.58B | $1.49B | $1.19B | |
| — | $228M | $203M | $300M | $132M | $148M | $88M | $62M | -$57M | $862M | -$124M | $97M | $44M | $337M | $236M | $363M | $417M | $451.9M | $411.25M | $411.93M | $343.89M | |
| — | $941M | $1.68B | $1.71B | $1.48B | $1.78B | $2.09B | $874M | $1.23B | $311M | $1.1B | $976M | $695M | $1.19B | $1.29B | $1.17B | $1.27B | $1.32B | $1.23B | $1.13B | $890.03M | |
| — | — | 7.68% | 8.45% | 7.66% | 9.43% | 10.94% | 5.44% | 7.13% | 1.95% | 9.1% | 7.82% | 6.76% | 14.03% | 16.05% | 15.18% | 16.76% | 18.49% | 17.63% | 16.34% | 14.17% | |
| — | — | $1.68B | $1.71B | $1.42B | $1.69B | $2B | $767M | $1.08B | $159M | $1.03B | $976M | $695M | — | — | — | — | — | — | — | — | |
| — | $1.11B | $1.52B | $1.52B | $1.42B | $2.38B | $2.55B | $609M | $859M | $125M | $1.31B | $786M | -$42M | $699M | $1.58B | — | — | — | $936.45M | $1.05B | $1.13B | |
| USD/shares | — | $2.00 | $4.58 | $4.62 | $3.91 | $4.66 | $5.44 | $2.16 | $3.08 | $0.48 | $3.60 | $3.52 | $2.63 | $4.70 | $5.09 | $4.36 | $4.41 | $4.31 | $3.93 | $3.54 | $2.78 |
| USD/shares | $12.62 – $12.72* | $2.00 | $4.58G | $4.61G | $3.88G | $4.62G | $5.39 | $2.13 | $3.02 | $0.46 | $3.53 | $3.44 | $2.57 | $4.59 | $4.98 | $4.29 | $4.31 | $4.21 | $3.83 | $3.42 | $2.68 |
| shares | — | — | 365.89M | 368.58M | 364.15M | 362.53M | 367.97M | 354.85M | 351.95M | 336.84M | 285.46M | 277.32M | 264.07M | 252.02M | 254.45M | 267.88M | 288.37M | 305.52M | 313.54M | 318.55M | — |
| shares | — | — | 366.98M | 370.16M | 366.83M | 365.53M | 371.54M | 359.22M | 358.25M | 345.01M | 291.51M | 283.62M | 270.55M | 257.77M | 259.71M | 272.73M | 295.02M | 313.09M | 321.78M | 329.45M | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2007–FY2025: $10.02B in buybacks, $12.92B in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
3.03×
Peer median 3.57×
EV/EBIT
29.37×
Peer median 33.13×
P/E (TTM)
—
Peer median 32.28×
Peer medians compare against the 14 similar-size Medical Instruments & Supplies companies (of 45 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Medical | $11,456,000,000 | $10,074,000,000 | $9,502,000,000 | $8,841,000,000 | $8,361,000,000 | $7,637,000,000 | $9,064,000,000 | $8,616,000,000 |
| Interventional | $5,217,000,000 | $4,980,000,000 | $4,736,000,000 | $4,464,000,000 | $4,239,000,000 | $3,762,000,000 | $3,926,000,000 | $3,037,000,000 |
| Life Sciences | $5,167,000,000 | $5,191,000,000 | $5,133,000,000 | $5,564,000,000 | $6,530,000,000 | $4,675,000,000 | $4,300,000,000 | $4,330,000,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| United States | $12,790,000,000 | $11,663,000,000 | $11,113,000,000 | $10,722,000,000 | $10,371,000,000 | $9,161,000,000 | $9,730,000,000 | $8,768,000,000 |
| Non Us | $9,049,000,000 | $8,515,000,000 | $8,258,000,000 | $8,148,000,000 | $8,760,000,000 | $6,912,000,000 | $7,560,000,000 | $7,215,000,000 |
| EMEA | $4,729,000,000 | $4,402,000,000 | $4,244,000,000 | $4,043,000,000 | $4,548,000,000 | $3,734,000,000 | $3,837,000,000 | — |
| Asia | $3,093,000,000 | $2,906,000,000 | $2,913,000,000 | $3,047,000,000 | $3,069,000,000 | $2,384,000,000 | $2,726,000,000 | $2,460,000,000 |
| Others Country | $1,227,000,000 | $1,207,000,000 | $1,102,000,000 | $1,058,000,000 | $1,142,000,000 | $794,000,000 | $997,000,000 | $1,457,000,000 |
| Middle East and Africa | — | — | — | — | — | $448,000,000 | $478,000,000 | — |
| Europe | — | — | — | — | — | $3,480,000,000 | $3,359,000,000 | $3,298,000,000 |
By Product & Service (USD)
| Component | FY2019 | FY2018 |
|---|---|---|
| Interventional Specialties Brachytherapyand Feeding Products | $185,000,000 | $194,000,000 |
| IV Fluids | $11,000,000 | $17,000,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Medical | $4,140,000,000 | $3,583,000,000 | $3,352,000,000 |
| Interventional | $2,253,000,000 | $2,115,000,000 | $1,939,000,000 |
| Life Sciences | $1,641,000,000 | $1,616,000,000 | $1,599,000,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Medical | 36.1% | 35.6% | 35.3% |
| Interventional | 43.2% | 42.5% | 40.9% |
| Life Sciences | 31.8% | 31.1% | 31.2% |
Key facts
CIK
10795
CUSIP
075887109
13F (30d)
969 filings
948 filers
Visit website
Investor relations